Wyeth buys UK’s Thiakis and gets hold of obesity compound
Wyeth is acquiring the privately-held UK biotechnology company Thiakis in a deal that could be worth around $150 million.
Read MoreAuthor: Kevin Grogan
Lilly/Daiichi Sankyo’s Efient gets backing of CHMP
Eli Lilly and Daiichi Sankyo are celebrating the news that regulators in Europe have recommended approval for their highly-anticipated bloodthinner prasugrel.
Read MorePfizer signs pact to sell drug for bent penis and Dupuytren’s
Pfizer has entered into a pact to develop and market Auxilium Pharmaceuticals’ late-stage biologic Xiaflex in a deal that could be worth up to $485 million to the Malvern, Pennsylvania-based firm.
Read MoreNiCox stock rises as naproxcinod Phase III analysis impresses
Shares in NicOx are on the rise after the French biotechnology firm presented a pooled analysis of late-stage data which shows that its investigational osteoarthritis treatment naproxcinod significantly reduces blood pressure among patients compared to the non-steroidal anti-inflammatory drug naproxen.
Read MoreB-MS to reduce workforce by an additional 10%
Bristol-Myers Squibb has revealed that it is going to cut an extra 10% of its global workforce by 2010, an expansion of a previously-announced cost-cutting plan.
Read More- AI system aims to uncover Alzheimer’s earlier and take on diagnostic delays
- Quell launches chill phase 1/2 trial for novel cartreg therapy
- Bioxytran reports positive phase 1b/2a results for antiviral ProLectin‑M
- FDA approves once‑weekly Sogroya for wider paediatric use
- SolasCure trial shows faster healing with Aurase Wound Gel
